Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S, alleging that the company made false or misleading statements regarding its CagriSema obesity study, leading to significant investor losses during the specified class period from November 2, 2022, to December 19, 2024 [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities during the class period and have until March 25, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Novo Nordisk failed to disclose critical information about the reliability of its projected success for the Phase 3 CagriSema obesity study, "REDEFINE-1" [5]. Group 2: Study Results and Impact - On December 20, 2024, Novo Nordisk reported results from the REDEFINE-1 trial, indicating that only 57.3% of CagriSema patients remained on the highest dose after 68 weeks, compared to 82.5% for cagrilintide 2.4 mg and 70.2% for semaglutide 2.4 mg [3]. - Following the release of these results, Novo Nordisk's stock price experienced a nearly 18% drop [3]. Group 3: Allegations of Misrepresentation - The lawsuit alleges that the company's claims regarding CagriSema achieving at least 25% weight loss in the REDEFINE-1 study were unrealistic [5]. - It is suggested that the study's "flexible protocol" limited its ability to provide meaningful weight loss data, indicating potential tolerability issues or a rushed patient selection process [5].